D-Ribose for Heart Failure

D-ribose is one of the more mechanistically defensible supplements in heart failure, because failing myocardium genuinely has depleted adenine nucleotide pools. What is missing is a trial large enough to change practice. Consider it only as an adjunct under cardiology supervision, never as a replacement for guideline therapy.

The failing heart loses adenine nucleotides faster than it can replace them, because de novo resynthesis is limited by the oxidative arm of the pentose phosphate pathway. Supplemental ribose enters downstream of that bottleneck and accelerates ATP pool restoration. Better ATP availability supports the energy-dependent calcium reuptake that governs diastolic relaxation, which is why the measured benefits appeared in diastolic rather than systolic parameters.

The best-known study is a randomised crossover trial in 15 patients with chronic coronary artery disease and congestive heart failure. Three weeks of 5 g three times daily improved echocardiographic diastolic filling parameters and physical-function quality-of-life scores compared with placebo, with no change in ejection fraction. A subsequent open-label study in 16 patients reported similar improvements in ventilatory efficiency during exercise. Mechanistic support is stronger than the clinical file. Animal ischaemia models consistently show faster ATP recovery with ribose, and human cardiac biopsy work confirms nucleotide depletion in failing myocardium. The gaps are serious. Total randomised exposure is fewer than 50 patients. No trial reports hard endpoints such as hospitalisation, functional class change over months, or mortality. Systematic reviewers have consistently rated the evidence insufficient to recommend routine use, and no adequately powered trial has been mounted since. Ribose also lowers blood glucose acutely, which matters because diabetes is common in heart failure populations.

Patients whose limitation is primarily systolic dysfunction or volume overload are unlikely to notice anything, since the measured benefit was in diastolic parameters. Anyone not already optimised on guideline-directed medical therapy should address that first.